EP
ABBV icon

EPIQ Partners’s AbbVie ABBV Stock Holding History

EPIQ Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$729K Sell
2,785
-200
-7% -$51.3K 0.31% 52
2026
Q2 		$751K Sell
2,985
-700
-19% -$151K 0.32% 50
2026
Q1 		$801K Hold
3,685
– – 0.37% 48
2025
Q4 		$842K Hold
3,685
– – 0.39% 46
2025
Q3 		$853K Hold
3,685
– – 0.4% 46
2025
Q2 		$684K Hold
3,685
– – 0.35% 47
2025
Q1 		$772K Hold
3,685
– – 0.41% 47
2024
Q4 		$655K Hold
3,685
– – 0.35% 48
2024
Q3 		$728K Hold
3,685
– – 0.4% 47
2024
Q2 		$632K Sell
3,685
-68
-2% -$11.3K 0.43% 43
2024
Q1 		$683K Sell
3,753
-13,827
-79% -$2.38M 0.45% 44
2023
Q4 		$2.72M Sell
17,580
-740
-4% -$108K 1.95% 22
2023
Q3 		$2.73M Sell
18,320
-885
-5% -$130K 2.06% 19
2023
Q2 		$2.59M Sell
19,205
-60
-0.3% -$8.8K 1.76% 22
2023
Q1 		$3.07M Buy
19,265
+40
+0.2% +$6.12K 2.12% 18
2022
Q4 		$3.11M Sell
19,225
-1,800
-9% -$276K 2.07% 19
2022
Q3 		$2.82M Buy
21,025
+975
+5% +$140K 1.75% 22
2022
Q2 		$3.07M Buy
20,050
+320
+2% +$48.9K 1.88% 21
2022
Q1 		$3.2M Buy
19,730
+1,800
+10% +$261K 1.72% 21
2021
Q4 		$2.43M Sell
17,930
-4,386
-20% -$518K 1.29% 31
2021
Q3 		$2.41M Buy
22,316
+3,850
+21% +$440K 1.11% 35
2021
Q2 		$2.08M Buy
18,466
+696
+4% +$78.4K 1.04% 35
2021
Q1 		$1.92M Buy
17,770
+1,375
+8% +$147K 1.1% 34
2020
Q4 		$1.76M Buy
16,395
+3,335
+26% +$320K 1.22% 33
2020
Q3 		$1.08M Sell
13,060
-700
-5% -$65.9K 0.82% 42
2020
Q2 		$1.35M Sell
13,760
-200
-1% -$17.6K 1.23% 32
2020
Q1 		$1.06M Buy
13,960
+475
+4% +$40.5K 1.18% 37
2019
Q4 		$1.19M Buy
+13,485
New +$1.12M 1.21% 36

Other funds holding ABBV

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Cardano Risk Management
Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return
Hamlin Capital Management
Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Ferguson Wellman Capital Management
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

EPIQ Partners's ABBV Position: Q3 2026 in Review

EPIQ Partners reduced its AbbVie (ABBV) stake by 6.7% in Q3 2026, selling an estimated $51.3K and leaving 2,785 shares worth $729K. The position accounts for 0.31% of the portfolio, ranked #52.

EPIQ Partners first reported a position in ABBV in Q4 2019 and has held it in 28 quarters since. The position peaked at $3.2M in Q1 2022. 1,083 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • EPIQ Partners held 2,785 shares of AbbVie worth $729K as of Q3 2026.
  • EPIQ Partners sold 200 AbbVie shares in Q3 2026, an estimated $51.3K.
  • AbbVie made up 0.31% of EPIQ Partners's portfolio in Q3 2026, its #52 holding.
  • EPIQ Partners first reported a position in AbbVie in Q4 2019 and has held it in 28 quarters since.
  • EPIQ Partners's AbbVie position peaked at $3.2M in Q1 2022.
  • 1,083 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on EPIQ Partners's 13F filing for Q3 2026, filed 7 Oct 2026.